MammaPrint BluePrint illuminating tumor biology

Optimizeย Endocrine Therapy Durationย in women with HR+/HER2-negative early breast cancer

NSABP-B42, IDEAL, and STO-3 demonstrate the ability of MammaPrint to identify a patient that:

> May REDUCE ET toย <5 yearsย in the event of intolerance1,2 (MP UltraLow)

> Show benefit from 10 yearsย of EET3,4ย (MP Low)

MammaPrint UltraLow Risk patients may consider <5 years of endocrine therapy

MammaPrint UltraLow Risk patients may consider <5 years of endocrine therapy1,2

Identifying MammaPrint UltraLow LN0 postmenopausal patients who have excellent 20-year BCSS with only 2 years of ET can prevent potential overtreatment and enable excellent outcomes with less toxic effects.1

*MammaPrint UltraLow is included in the 2023ย NCCN Guidelinesย โ€˜Gene Expression Assays for Consideration of Adjuvant Systemic Therapyโ€™ Visit www.nccn.org to learn more

MammaPrint predicts benefit from extended endocrine therapy in postmenopausal Low Risk patients

MammaPrint predicts benefit from extended endocrine therapy
in postmenopausal Low Risk patients.3,4

Recent data demonstrate that MammaPrint High 2, BluePrint Luminal B, is predictive of benefit from AC-T therapy, with a higher 3-year RFS rate than with TC therapy, alone.

*Data shown in bar chart is from NSABP-B42

Dive deeper into the data with our Medical team

Request Data Review / Additional Data:
* indicates required
Select the data you would like to learn more about